Vanguard Capital Management
ABVC icon

Vanguard Capital Management’s ABVC BioPharma ABVC Stock Holding History

Vanguard Capital Management’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$592K Buy
374,499
+183,925
+97% +$229K ﹤0.01% 3686
2026
Q1 		$185K Buy
+190,574
New +$315K ﹤0.01% 3810

Other funds holding ABVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management's ABVC Position: Q2 2026 in Review

Vanguard Capital Management increased its ABVC BioPharma (ABVC) stake by 97% in Q2 2026, buying an estimated $229K and bringing the position to 374,499 shares worth $592K. The position accounts for ﹤0.01% of the portfolio, ranked #3686.

Vanguard Capital Management first reported a position in ABVC in Q1 2026 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

  • Vanguard Capital Management held 374,499 shares of ABVC BioPharma worth $592K as of Q2 2026.
  • Vanguard Capital Management bought 183,925 ABVC BioPharma shares in Q2 2026, an estimated $229K.
  • ABVC BioPharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3686 holding.
  • Vanguard Capital Management first reported a position in ABVC BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.